<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>Chronic Kidney Disease on Guia GLP-1 — Ozempic, Wegovy, Mounjaro</title><link>https://glp1decode.com/pt/tags/chronic-kidney-disease/</link><description>Recent content in Chronic Kidney Disease on Guia GLP-1 — Ozempic, Wegovy, Mounjaro</description><image><title>Guia GLP-1 — Ozempic, Wegovy, Mounjaro</title><url>https://glp1decode.com/images/default-og.png</url><link>https://glp1decode.com/images/default-og.png</link></image><generator>Hugo</generator><language>pt</language><lastBuildDate>Fri, 19 Jun 2026 00:00:00 +0000</lastBuildDate><atom:link href="https://glp1decode.com/pt/tags/chronic-kidney-disease/index.xml" rel="self" type="application/rss+xml"/><item><title>Ozempic e saúde renal: o que o estudo FLOW significa para você</title><link>https://glp1decode.com/pt/posts/ozempic-kidney-health-2026/</link><pubDate>Fri, 19 Jun 2026 00:00:00 +0000</pubDate><guid>https://glp1decode.com/pt/posts/ozempic-kidney-health-2026/</guid><description>O estudo FLOW mostrou que a semaglutida protege os rins em pessoas com diabetes tipo 2 e doença renal crônica. Veja o que os dados significam e quem se beneficia mais.</description></item></channel></rss>